86 related articles for article (PubMed ID: 1756253)
1. Plasma coagulation and fibrinolysis parameters in patients with collagen diseases, and analysis of the multimeric structure of von Willebrand factor (vWF).
Kagawa H; Okubo S; Yasunaga K
Int J Hematol; 1991 Oct; 54(5):429-39. PubMed ID: 1756253
[TBL] [Abstract][Full Text] [Related]
2. [Plasma coagulation and fibrinolysis parameters in patients with vascular Behçet's disease, and analysis of the multimeric structure of von Willebrand factor (vWF)].
Kagawa H; Okubo S
Ryumachi; 1993 Oct; 33(5):416-23. PubMed ID: 8256164
[TBL] [Abstract][Full Text] [Related]
3. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
4. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease.
Weiss HJ; Pietu G; Rabinowitz R; Girma JP; Rogers J; Meyer D
J Lab Clin Med; 1983 Mar; 101(3):411-25. PubMed ID: 6186757
[TBL] [Abstract][Full Text] [Related]
6. [Regulation of coagulo-fibrinolytic activity and lupus anticoagulants in systemic lupus erythematosus].
Fusegawa H; Ichikawa Y; Tanaka Y; Shiba T; Kawada T; Shimizu H; Moriuchi J; Arimori S; Ando Y
Ryumachi; 1990 Apr; 30(2):90-8. PubMed ID: 2122531
[TBL] [Abstract][Full Text] [Related]
7. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
[TBL] [Abstract][Full Text] [Related]
8. [Coagulation and fibrinolytic parameters in patients with various angiopathies--analysis in cerebral thrombosis, diabetic and vasculitic neuropathies].
Kohriyama T; Katayama S; Tanaka E; Yamamura Y; Nakamura S
Rinsho Shinkeigaku; 1993 Jun; 33(6):606-11. PubMed ID: 8403679
[TBL] [Abstract][Full Text] [Related]
9. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
10. Endothelial cell activation in cutaneous vasculitis.
Jurd KM; Stephens CJ; Black MM; Hunt BJ
Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
Neugebauer BM; Goy C; Budek I; Seitz R
Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
[TBL] [Abstract][Full Text] [Related]
12. Addition of serum from patients with collagen diseases increases to cultured human endothelial cells production and release of von Willebrand factor.
Kagawa H; Okubo S; Iwata K; Nomura S; Yasunaga K
Am J Hematol; 1993 Mar; 42(3):309-15. PubMed ID: 8438904
[TBL] [Abstract][Full Text] [Related]
13. Autoantibody to von Willebrand factor in systemic lupus erythematosus.
Soff GA; Green D
J Lab Clin Med; 1993 Mar; 121(3):424-30. PubMed ID: 8445290
[TBL] [Abstract][Full Text] [Related]
14. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
Turecek PL; Siekmann J; Schwarz HP
Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
[TBL] [Abstract][Full Text] [Related]
15. [Long-term hemodialysis and changes in variables of coagulation and fibrinolysis].
Uchida Y
Fukuoka Igaku Zasshi; 1991 Nov; 82(11):576-85. PubMed ID: 1774013
[TBL] [Abstract][Full Text] [Related]
16. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
17. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.
Ribba AS; Loisel I; Lavergne JM; Juhan-Vague I; Obert B; Cherel G; Meyer D; Girma JP
Thromb Haemost; 2001 Sep; 86(3):848-54. PubMed ID: 11583318
[TBL] [Abstract][Full Text] [Related]
18. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus.
Viallard JF; Pellegrin JL; Vergnes C; Borel-Derlon A; Clofent-Sanchez G; Nurden AT; Leng B; Nurden P
Br J Haematol; 1999 May; 105(2):532-7. PubMed ID: 10233433
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetics of von Willebrand disease.
Mazurier C; Ribba AS; Gaucher C; Meyer D
Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
[TBL] [Abstract][Full Text] [Related]
20. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
